Using X-ray imaging of post mortem brains, researchers from Osaka University find α-synuclein aggregates that can move through the brain before developing into Lewy bodies, the hallmark of Parkinson's disease
The seeds of Parkinson's disease: amyloid... - Cure Parkinson's
The seeds of Parkinson's disease: amyloid fibrils that move through the brain
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
![](https://images.hu-production.be/post/post_f8641a10bb184432a37e23bc9cbc2626_637031157159416000.jpg)
![Farooqji profile image](https://images.hu-production.be/avatars/d2bcede6695608a9d172b4c00f6b376c_small@2x_100x100.jpg)
Iq-
Again you are excellent at finding interesting articles, but I think it imperative that you add some discussion so folks can understand what is or is not of value. My interpretation of this study is first that Parkinson's Disease is NOT "prion like" meaning you can't "catch" the disease from someone else, and second I disagree completely that aggregation is part of the toxicity of alpha-synuclein. People can do their own research, but here is but one of many papers that came to this conclusion and here is a quote from the paper:
-
α-Synuclein misfolding and Parkinson's disease
sciencedirect.com/science/a...
"This data allows us to make a conclusion that, similar to other neurodegenerative diseases, there is a lack of correlation between α-synuclein fibril accumulation and neurotoxicity, making it likely that oligomers are the neurotoxic species."
-
It is my opinion and the reason for all my post on HU related to Parkinson's that alpha-synuclein becomes toxic in patients with Parkinson's because it forms an oligomer, and THAT is the single common denominator in the majority of Parkinson's cases. The problem lies in the variation in the cause of the mutation AND the type of mutation.
-
Here are several studies and articles that underly my belief:
ncbi.nlm.nih.gov/pubmed/295...
scienceofparkinsons.com/201...
ncbi.nlm.nih.gov/pubmed/294...
ncbi.nlm.nih.gov/pmc/articl...
and a Phase 2 clinical trial of a drug for the treatment of Parkinson's based on the theory of alpha-sy as a toxic oligomer:
-
Cheers,
Joe in NY
Thank you, Joe, for sharing this important information! Your thorough research into characteristics of alpha-synuclein, is intriguing.
Still trying to get through all of your links but I keep getting sidetracked by other information and chasing rabbit holes, one of which is Ecoli and it's effect on alpha synuclein, oxidative stress, peptides as immunotherapy, lymphocyte-activation gene 3, known as LAG3, misfolded PrP90-231 and on and on. Not sure if this has been read or discussed, lots of interesting things being discovered.
Definitely something to this...and I think that Joe is correct.